<DOC>
	<DOCNO>NCT00098007</DOCNO>
	<brief_summary>The study design evaluate whether Neoral dose optimization together therapeutic drug monitoring Certican prevent renal dysfunction observe pivotal cardiac trial maintain efficacy . This objective assess compare renal function post-transplant 2 group patient .</brief_summary>
	<brief_title>A Study Safety , Tolerability &amp; Efficacy Certican de Novo Heart Transplant ( Tx ) Patients</brief_title>
	<detailed_description />
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<criteria>Inclusion criterion Male female cardiac patient 1865 year old undergoing primary heart transplantation . Females potential childbearing age must negative serum pregnancy test within 7 day prior enrollment . Effective contraception must use trial 6 week follow discontinuation study medication , even history infertility . Patients willing able participate full course study write informed consent obtain . Exclusion criteria Patients donor heart great 60 year age and/or cold ischemia time 6 hour and/or donor heart obvious coronary disease know heart disease time transplant . Patients recipients multiple solid organ transplant , previously receive transplanted organ . Patients receive investigational drug treat immunosuppressive drug treatment within 4 week prior study entry . Patients serum creatinine level &gt; 250 mol/L . Patients platelet count ≤ 50,000/mm3 white blood cell count ≤ 2,500/mm3 . Patients active systemic infection , accord investigator judgment , require continue therapy . Patients know hypersensitivity mTOR inhibitor . Patients Panel Reactive Antibodies ≥ 25 % . Presence severe hypercholesterolemia ( ≥ 350mg/dL ; ≥9 mmol/L ) hypertriglyceridemia ( ≥ 750 mg/dL ; ≥ 8.5 mmol/L ) . Presence severe allergy require acute ( within 4 week baseline ) chronic treatment , hypersensitivity drug similar Certican ( e.g. , macrolides ) . Symptoms significant mental illness , opinion investigator may interfere patient ability comply protocol . History drug alcohol abuse within 1 year baseline . Patients past ( within last 5 year ) present malignancy excise squamous basal cell carcinoma . Patients history significant coagulopathy medical condition require longterm anticoagulation transplantation ( low dose aspirin treatment allow ) . Abnormal physical laboratory finding clinical significance within 2 week prior study entry would interfere objective study . Inability cooperate communicate investigator . Female childbearing potential planning become pregnant , pregnant and/or lactating , unwilling use effective mean contraception . Breast feeding woman . Patients recipient ABO incompatible transplant . Patients know chronic active Hepatitis C ( PCR+ ) , HIV Hepatitis B surface antigen positive . Laboratory result obtain within 6 month prior randomization acceptable . Recipients organs donor test positive Hepatitis B surface antigen Hepatitis C ( PCR+ ) exclude</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Heart transplantation</keyword>
	<keyword>Everolimus</keyword>
	<keyword>De novo heart transplant patient</keyword>
</DOC>